When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innovation. It reinforces the notion that India-based ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Saldanha said he hasn’t yet fully figured out how to deploy much of the proceeds of the licensing deal, but added that he ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a three-day winning streak.

Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data ...

Investors are digesting Trump's stiff tariffs on imports from more than a dozen countries and delayed the return of sweeping April levies.

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging drugs, market share of individual therapies, and ...

Global active pharmaceutical ingredients (API) market will reach $ 386.2 billion by 2032, growing by 6.4% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...